Suppliers / Alivus Life Sciences

Alivus Life Sciences

India ALIVUS.NS 590 employees 2 duplicate records merged Updated 9 July 2026

Alivus Life Sciences is an API manufacturer based in India. It holds 272 active US drug master files and 43 valid CEPs. Its GMP standing is certified by US FDA and EMA. Its most recent recorded inspection, by US FDA, closed on 30 May 2025 as NAI. Customs aggregates show $58.5M of exports covering 903 molecules to 62 destinations in 2025.

272
active US DMFs
43
valid CEPs
4
registered plants 3 with an FDA FEI number
2
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
3 of 3 confirmed
Inspections
8 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 30 May 2025 NAI US FDA
  • 31 January 2025 VAI US FDA
  • 5 July 2019 VAI US FDA
  • 26 October 2018 NAI US FDA
  • 16 December 2016 VAI US FDA
  • 17 April 2015 VAI US FDA
  • 27 February 2015 VAI US FDA
  • 15 October 2011 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Mumbai, India Not on file
Bharuch, India 3007514214
Solapur, India 3014026060
Ankleshwar, India 3004006229

What they file, and where

Molecule Regulators Docs
Esomeprazole EDQM, US FDA 9
Rosuvastatin EDQM, US FDA 7
Atovaquone EDQM, US FDA 6
Ezetimibe US FDA 6
Sitagliptin US FDA 6
Aprepitant EDQM, US FDA 5
Tadalafil EDQM, US FDA 5
Telmisartan EDQM, US FDA 5
Terbinafine EDQM, US FDA 5
Zolpidem EDQM, US FDA 5
Show all 30 molecules on file
Bupropion US FDA 4
Desloratadine EDQM, US FDA 4
Fluconazole EDQM, US FDA 4
Glimepiride EDQM, US FDA 4
Linezolid US FDA 4
Sucralfate US FDA 4
Tafamidis US FDA 4
Zonisamide US FDA 4
Adapalene EDQM, US FDA 3
Amiodarone EDQM, US FDA 3
Brivaracetam EDQM, US FDA 3
Deferasirox EDQM, US FDA 3
Dipyridamole EDQM, US FDA 3
Fingolimod EDQM, US FDA 3
Lacosamide EDQM, US FDA 3
Mirabegron EDQM, US FDA 3
Perindopril SFDA (Saudi Arabia), US FDA 3
Pirfenidone EDQM, US FDA 3
Rivaroxaban EDQM, US FDA 3
Rizatriptan EDQM, US FDA 3

Also appears on these molecule pages

Show 30 more molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
MINSA (CR) 2 None
US FDA None 2
EMA None 1

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $10.7M 50
2025 Not reported $58.5M 62
2021 $255.0M Not reported Not reported
2020 $15.4B Not reported Not reported
2019 $8.9B Not reported Not reported

Export figures are customs aggregates. We do not publish the identity of any buyer. Revenue shown in US dollars, converted from the reported currency.

Comparing suppliers?

Choose your molecules and target markets. Alivus Life Sciences comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 30 May 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts
Company filings
Revenue as reported